I'm LongbridgeAI, I can summarize articles.McKesson (MCK) gained 1.63% this week to close at $907.99. The S&P 500 rose just 0.09% over the same period, leaving McKesson roughly 1.54 percentage points ahead of the benchmark. The stock opened lower on Monday at $876.482, then climbed steadily through the week, reaching $906.77 on Tuesday and $924.78 on Wednesday. Thursday brought a session high of $929.95 before a small pullback on Friday to $907.99. The weekly amplitude of 6.
The Week
McKesson (MCK) gained 1.63% this week to close at $907.99. The S&P 500 rose just 0.09% over the same period, leaving McKesson roughly 1.54 percentage points ahead of the benchmark. The stock opened lower on Monday at $876.482, then climbed steadily through the week, reaching $906.77 on Tuesday and $924.78 on Wednesday. Thursday brought a session high of $929.95 before a small pullback on Friday to $907.99. The weekly amplitude of 6.06% was wider than the recent trading range around the 20-day moving average of $883.614.
Key Events
A data security story dominated the week. On 1 September, hackers claimed to have stolen millions of patient records during a data breach at McKesson. Ahead of the open, the stock was up 4.89% in pre-market trading, and it closed the day 3.13% higher. McKesson did not issue an immediate official confirmation. Separately, Continuum Advisory LLC disclosed a purchase of McKesson shares on 3 September. Media coverage on 4 September placed McKesson among medical and pharmaceutical stocks worth researching, though Friday’s comparison showed the stock underperforming some competitors. Overall, the week lacked company-level earnings or major business updates, with the breach claim and an institutional trade disclosure carrying the narrative.
Analyst Ratings
The latest coverage shows 11 buy ratings, 3 overweight ratings and 4 hold ratings, with no underweight or sell ratings across 18 analysts. The consensus rating is buy, and the consensus target price of $980.73 sits about 8.01% above the current $907.99. Target prices range from $845.00 to $1,065.00, a wide spread of roughly $220 that points to meaningful disagreement on valuation. Within the medical products distributor industry, McKesson ranks first, with more covering analysts than the industry average of 9. The rating picture leans supportive, but the broad target range suggests the market has not settled on a single valuation anchor.
The Week Ahead
Macro data will set the tone next week. The US NFIB small business optimism index lands on 8 September, following a prior reading of 99.8. On 10 September, the calendar is heavy: initial jobless claims (prior 206, forecast 205), final demand PPI, core final demand PPI, existing home sales, wholesale sales, and EIA natural gas storage will all be released. The PPI prints are in focus, with forecasts running slightly above prior values. None of these are McKesson-specific, but shifts in rate expectations and health-care risk appetite could feed back into the stock.
In Short
McKesson held its gains through a week defined by an unconfirmed data breach claim, finishing at $907.99 and beating the S&P 500 by about 1.54 percentage points. On valuation, the stock trades at roughly 23.05 times earnings, with a negative price-to-book ratio, so it does not sit in a cheap valuation bucket. The latest funding snapshot shows no clear large-lot flow, modest medium-lot net buying and small-lot net selling, a divided picture rather than a firm directional signal. The buy-leaning analyst consensus and a target above spot provide an upward pull, but the wide target range and Friday’s fade point to real two-way tension near $900. The next reads are the data breach narrative and next week’s U.S. PPI and labour market data.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.